Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.76)
# 122
Out of 5,113 analysts
43
Total ratings
66.67%
Success rate
38.05%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRXS NeurAxis | Maintains: Buy | $7 → $8 | $4.68 | +70.94% | 2 | Dec 22, 2025 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $43.83 | +46.02% | 4 | Sep 23, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.69 | +82.05% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.55 | +185.71% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.48 | +47.06% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $8.53 | +29.03% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $4.43 | -32.28% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $14.07 | +20.82% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $15.11 | +85.31% | 6 | May 14, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $17.98 | +116.91% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $5.18 | +54.44% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.55 | +99.05% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $5.63 | +6.67% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $5.25 | +128.57% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.08 | +23.76% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $21.57 | +6.63% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.64 | +88.98% | 2 | Jul 11, 2023 |
NeurAxis
Dec 22, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.68
Upside: +70.94%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $43.83
Upside: +46.02%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.69
Upside: +82.05%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.55
Upside: +185.71%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.48
Upside: +47.06%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.53
Upside: +29.03%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $4.43
Upside: -32.28%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $14.07
Upside: +20.82%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $15.11
Upside: +85.31%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $17.98
Upside: +116.91%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $5.18
Upside: +54.44%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.55
Upside: +99.05%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $5.63
Upside: +6.67%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $5.25
Upside: +128.57%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.08
Upside: +23.76%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $21.57
Upside: +6.63%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.64
Upside: +88.98%